Trends in Cardiovascular Medicine
Volume 17, Issue 4 , Pages 134-140, May 2007

Embryonic Stem Cells for Cardiac Muscle Engineering

  • Wolfram-Hubertus Zimmermann

      Affiliations

    • Corresponding Author InformationAddress correspondence to: Wolfram-Hubertus Zimmermann, MD or Thomas Eschenhagen, MD, Institute of Experimental and Clinical Pharmacology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany. Tel.: +(49) 40-42803-2180; fax: +(49) 40-42803-4876
  • ,
  • Thomas Eschenhagen

      Affiliations

    • Corresponding Author InformationAddress correspondence to: Wolfram-Hubertus Zimmermann, MD or Thomas Eschenhagen, MD, Institute of Experimental and Clinical Pharmacology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany. Tel.: +(49) 40-42803-2180; fax: +(49) 40-42803-4876

Institute of Experimental and Clinical Pharmacology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.

The aim of cardiac tissue engineering is twofold: (1) to provide three-dimensional cardiac tissue to restore the function of diseased hearts and (2) to develop improved test beds for target validation and substance screening. Both concepts have been successfully demonstrated by several groups using immature primary heart cells, but these cells are essentially postmitotic, precluding clinical and large-scale in vitro applications. Identification of a renewable cell source is therefore one of the key objectives in the field. Embryonic stem (ES) cells are attractive candidates because they can be propagated in large quantities, have a robust capacity to differentiate into cardiac myocytes, and can be obtained from humans. Classic isolation of ES cells from the inner cell mass is associated with destruction of the respective embryo. Thus, alternative technologies to generate stem cell lines with ES cell properties are inevitably called for. This review discusses the usefulness of ES cells in cardiac tissue engineering and alternative, embryo-sparing technologies to derive ES cells.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1050-1738(07)00051-5

doi:10.1016/j.tcm.2007.02.007

Trends in Cardiovascular Medicine
Volume 17, Issue 4 , Pages 134-140, May 2007